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Summary
The oculocerebrorenal syndrome of Lowe (OCRL) is an
X-linked disorder characterized by major abnormalities
of eyes, nervous system, and kidneys. Mutations in the
OCRL1 gene have been associated with the disease.
OCRL1 encodes a phosphatidylinositol 4,5-biphosphate
(PtdIns[4,5]P2) 5-phosphatase. We have examined the
OCRL1 gene in eight unrelated patients with OCRL and
have found seven new mutations and one recurrent in-
frame deletion. Among the newmutations, two nonsense
mutations (R317X and E558X) and three other frame-
shift mutations caused premature termination of the pro-
tein. A missense mutation, R483G, was located in the
highly conserved PtdIns(4,5)P2 5-phosphatase domain.
Finally, one frameshift mutation, 2799delC, modifies the
C-terminal part of OCRL1, with an extension of six
amino acids. Altogether, 70% of missense mutations are
located in exon 15, and 52% of all mutations cluster in
exons 11–15. We also identified two new microsatellite
markers for the OCRL1 locus, and we detected a germ-
line mosaicism in one family. This observation has direct
implications for genetic counseling of Lowe syndrome
families.
Introduction
The oculocerebrorenal syndrome of Lowe (OCRL [MIM
309000]) is a rare X-linked disorder characterized by a
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severe pleiotropic phenotype including mental retarda-
tion, congenital cataract and renal Fanconi syndrome
(Lowe et al. 1952). The OCRL1 gene has been mapped
to chromosome Xq24.26 (Silver et al. 1987) and cloned
(Attree et al. 1992). Its genomic structure has been re-
cently described (Nussbaum et al. 1997). The coding
region includes exons 2–23, with an alternative spliced
exon (18a) expressed in neurological tissues (Nussbaum
et al. 1997). The gene product is an inositol polyphos-
phate 5-phosphatase, belonging to the inositol 5-phos-
phatase gene family and characterized by two conserved
amino acid domains involved in substrate binding and
catalysis (Jefferson et al. 1996). Inositol 5-phosphatases
have been characterized by their substrate specificity,
leading to their classification as type I or type II phos-
phatases. The former act on the soluble head-group in-
ositol polyphosphate, whereas type II phosphatases can
also employ lipid substrates (Woscholski and Parker
1997). The OCRL1 protein was first localized in fibro-
blasts associated with the Golgi apparatus (Olivos-Glan-
der et al. 1995; Suchy et al. 1995). The protein may
control cellular levels of phosphatidyl inositol 4,5-bi-
phosphate [PtdIns(4,5)P2], a critical metabolite that is
involved in Golgi vesicular transport. Recently, a study
performed on kidney proximal tubule cells compared
the properties of full-length OCRL1 with those of a trun-
cated OCRL1 still encoding the region homologous to
the 5-phosphatase II. It showed that only the normal
protein is associated with lysosomal membranes and that
OCRL1 may function by regulating the lysosomal pool
of PtdIns(4,5)P2.
The majority of OCRL patients have either no de-
tectable OCRL1 mRNA (Attree et al. 1992) or no de-
tectable 5-phosphatase activity (Lin et al. 1997), sug-
gesting that a loss of OCRL1 function is the cause of
Lowe syndrome. Although most of the reported muta-
tions are nonsense and frameshift mutations leading to
a truncated protein, missense mutations and short in-
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frame deletions have been also reported (Leahey et al.
1993; Lin et al. 1997; Kawano et al. 1998; Kubota et
al. 1998; Lin et al. 1998). Only one case of a 1.2-kb
genomic deletion leading to the loss of exon 14 has been
described so far (Lin et al. 1997). This suggests that exon
deletion is not a common mechanism of mutation in
Lowe syndrome.
X-linked recessive diseases are characterized by the
frequent occurrence of spontaneous mutations (Haldane
1935), and different mutations are to be expected in
independent families. However, recurrences of nonsense
and missense mutations have been described in unrelated
patients (Leahey et al. 1993; Lin et al. 1997). We report
here on the genetic study of eight families, seven Eu-
ropean and one Lebanese. The search for mutations was
performed on genomic DNA from the affected male pa-
tients. Eight mutations were identified, including seven
newly identified mutations and one recurrent mutation
previously described in a North American family. Ger-
minal mosaicism is a major problem in risk estimation
for an X-linked disease (Murphy et al. 1974). With the
development of direct mutation detection, germinal mo-
saicism has been demonstrated in a majority of severe
dominant diseases as well as in X-linked diseases. How-
ever, no germinal mosaicism had yet been reported in
families affected by Lowe syndrome. We performed hap-
lotyping of the families in order to determine the origin
of the mutation in the different families. Using new
closely linked flanking markers from Ge´ne´thon, we
found in one family a germline mosaicism in the grand-
mother. This finding confirms that mosaicism is a general
phenomenon accompanying new mutations in X-linked
recessive disorders and must now be taken into account
in genetic counseling of families with Lowe syndrome.
Material and Methods
Samples from Patients
The study included eight families, originating from
France (LS01FR, LS02FR, LS04FR, and LS07FR), Spain
(LS03ES, LS05ES, and LS06LS), and Lebanon (LS08LI)
(fig. 1). Five of these eight pedigrees had a family history
of at least two male patients carrying a clinical diagnosis
of Lowe syndrome on the basis of the classic triad of
defects affecting lens, brain and kidney. In one family
(LS06ES), the two affected sons were deceased. The
search for mutations in OCRL1 in this family was per-
formed on the DNA of the carrier mother, who herself
presented ocular symptoms. Blood was collected from
the affected patients, from their parents, and from rel-
atives, with the informed consent of all. When necessary
buccal swabs, hair roots, and urinary cells were col-
lected, to investigate somatic mosaicisms.
DNA Extraction and Amplification
Genomic DNA was extracted from whole blood by a
rapid guanidine method (Jeanpierre 1987). When hair-
root, buccal-swab, and urinary cells were analyzed, ge-
nomic DNA was extracted by Chelex following the man-
ufacturer’s instructions. The 23 coding exons ofOCRL1
and their flanking intronic sequences were amplified us-
ing forward and reverse primers, as described by Nuss-
baum et al. (1997). Reactions were performed in a 25-
ml mix containing 100 ng genomic DNA, 200 mM of
each dNTP, 1 mM each of forward and reverse primers,
0.5 U Taq polymerase (Promega), and 1.5 mM MgCl2,
except for the amplification of exon 16, which was per-
formed with 2.5 mM MgCl2. A 95C denaturation step
of 5 min was followed by 30–32 amplification cycles
with the following parameters: 94C for 30 s, an an-
nealing step for 30 s, and 72C for 1 min.
Single Strand Conformation Analysis (SSCA)
Each exon was amplified as described above in the
presence of 1 mCi -a[32P]-dCTP(10 Ci/mmol). PCR
products were denatured in loading buffer (95% for-
mamide, 0.01 M NaOH, 0.025% xylene cyanol,
0.025% bromophenol blue) at 95C for 2 min, were
cooled on ice and were separated on a nondenaturating
DNA-sequencing gel prior to autoradiography. Two sep-
arating conditions were used for each sample: a run on
a 6% acrylamide gel at 4C and 40 W for 2 to 3 h, and
a run on a 6% acrylamide/10% glycerol gel at room
temperature and 4 W overnight.
Sequencing
PCR-amplified fragments obtained from genomic
DNA were purified by use of the QIAquick DNA-pu-
rification system (Qiagen). To eliminate any sequence
due to faulty polymerase activity, products from three
independent amplifications were sequenced on an an ABI
373 apparatus, with the PCR primers used as sequencing
primers.
Haplotyping and Data Analysis
DNA from family members was typed by two flanking
microsatellite-repeat markers described by Nussbaum et
al. (1997): DXS6854 and DXS6855. Additional CA-re-
peat markers from Ge´ne´thon—DXS994, DXS1047, and
DXS1206—were tested for linkage to the OCRL1 locus.
Primer sequences and allele sizes have been previously
reported (Weissenbach et al. 1992).
For each primer pair, 0.4 pmol forward primer was
5’ end-labeled with [32P] and was added to a 25-ml PCR
mix containing 50 ng genomic DNA, 200 mM each
dNTP, 1 mM each of forward and reverse primers, and
0.25 U Taq polymerase (Applige`ne). Amplification was
Figure 1 Segregation of mutations and of chromosome-X markers in families with Lowe syndrome. Patients with OCRL syndrome are indicated by blackened symbols. The presence of the
OCRL1 mutation is indicated by a plus sign () or a minus sign (). Results of typing for the polymorphic microsatellite markers—DXS1206, DXS1047, DXS6854, OCRL1 mutation, DXS6855,
DXS994, and HPRT—are shown in order, from top to bottom. For clarity of presentation, alleles associated with the disease are boxed. Arrows indicate recombination events.
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Table 1
Mutations of the OCRL1 Gene Identified in Eight Patients with Lowe Syndrome
Family Exon Mutation Type DNA Changea Predicted Protein Change Screening Methodb
LS01FR 11 1-bp insertion 1152insA Frameshift and stop SspI ()
LS03ES 11 Nonsense C1177T R317X TaqI ()
LS06EX 12 3-bp deletion 1276delAAC DT350 or 351c Heteroduplex
LS04FR 15 Missense C1738G R483G SSCA
LS07FR 16 4-bp deletion 1856delCTTC or 1859delCCTT Frameshift and stop Heteroduplex
LS05ES 17 1-bp deletion 1954 delG Frameshift and stop SSCA
LS08LI 17 Nonsense G1900T E558X MseI ()
LS02FR 23 1-bp deletion 2799delC Change of the C-terminus, starting at codon 860 BslI ()
a Base number is according to GenBank entry U57627.
b Used to screen the mutation in the family members : ()  creation of a restriction site; ()  loss of a restriction site.
c Recurrent mutation (Lin et al. 1997)
performed for 25–30 running cycles with the following
parameters: 30 s at 94C, 30 s at the annealing tem-
perature (60C for DXS994, DXS1047, and DXS1206)
and 1 min at 72C. After denaturation with formamide,
amplified products were separated on a 8% polyacryl-
amide/8 M urea DNA-sequencing gel prior to autora-
diography. Consecutive allele numbers were assigned,
and the results were documented by Cyrillic 2.0 software
(Cherwell Scientific Publishing). Two-point linkage anal-
ysis was performed by means of the LINKAGE 5.2 pack-
age (Lathrop and Lalouel 1984). Parameters were set as
follows: the disease-allele frequency at 105, the disease
penetrance at 1.0, and the OCRL mutation rate at 106.
Results
Identification of Mutations
The 23 coding exons and the exon-intron boundaries
of the OCRL1 gene were screened by SSCA. An aberrant
migration of certain fragments was found in each family.
Sequencing of the corresponding exons led to the iden-
tification of seven new mutations and of one recurrent
mutation (table 1). This last mutation was an in-frame
triple-base deletion that led to the deletion of a well-
conserved threonine residue at position 350 or 351 (Lin
et al. 1997). Four patients carried a short out-of-
frame deletion or insertion—1152insA, 1954delG,
1856delCTTC, or 1859delCCTT—leading, for three pa-
tients, to a premature termination of the protein. Inter-
estingly, the frameshift mutation 2799delC in exon 23
led to a change of the C-terminal domain of the protein:
the last 25 amino acids MARQTPSDRQRAQFLLG-
FLLGSEED were lost and were replaced by the following
32 amino acids: WQDRLQVTASVLFSSFWAFCLGA-
KKTKAFTVL. This clearly introduced changes in the
conformational and charge properties of the C-terminal
domain. The last three acidic amino acids (EED) of the
native protein were replaced in the mutated OCRL1 by
four amino acids (KKTK), three of which were positively
charged. Predictive structure analysis using the Protean
software (DNASTAR) showed that both surface prob-
ability and hydrophilicity plots of the C-terminal part
of the mutated protein differed from those of the normal
OCRL1. Thus, the C-terminal domain of the mutated
OCRL1 appeared to be less exposed at the surface of
the protein. Two nonsense mutations, R317X and
E558X, and one missense mutation, R483G, were also
found in the three last families. To screen the family
members for the identified mutations, we investigated a
possible change in enzymatic restriction sites, introduced
by the different mutations. Three changes created a new
restriction site, and one abolished an existing site. This
allowed us to propose a simple test for prenatal diagnosis
after identification of all the carriers in the respective
families. Two other mutations could be investigated by
a rapid heteroduplex method (table 1). In all families
tested, the identified OCRL1 mutations were associated
only with the disease phenotype or with a carrier status.
An additional polymorphism in exon 17, leading to a E
to G substitution at position 568, was found in families
LSO5ES, LSO6ES, and LSO7FR. This position does not
correspond to a conserved amino acid when one com-
pares protein sequences of various inositol-5-phos-
phatases.
Neomutation and Germline Mosaicism
To determine the origin of the mutation in the differ-
ent families, we performed haplotyping of the families
(fig. 1). As a first step, and to obtain as much informa-
tion as possible, new microsatellite markers from Ge´-
ne´thon were characterized at the OCRL1 locus. We
identified two markers, DXS1047 and DXS994, which
are closely linked to the OCRL1 locus (maximum LOD
scores of 18.8 and 14.5, respectively, at ). However,v  0
the absence of recombinants between these markers and
Lowe syndrome did not allow us to localize them as
distal or proximal from OCRL1. Thus, the deduced ge-
netic map of the OCRL1 locus on chromosome Xq26.1
is as follows: cen–DXS1206–(8 cM)–(DXS6854–
[DXS1047, DXS994, OCRL1]–DXS6855)–(4 cM)–
HPRT–tel. These new markers, together with the already
described flanking markers DXS6854 and DXS6855
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Figure 2 SSCA of c1738g mutation in different tissues of obligate-carrier grandmother in family LS04FR. SSCA was performed as described
in Material and Methods. The left panel shows the SSCA profiles of exon 15, amplified from DNA samples extracted from different tissues
(blood, hair roots, buccal swabs, and urinary cells) and from different individuals: I-2 (obligate-carrier grandmother), II-4 (carrier mother), and
III-4 (affected child). Lane 1, Blood of the grandmother; Lane 2, Hair-root cells of grandmother; Lane 3, Buccal swab of grandmother; Lane
4, urinary cells of grandmother; Lane 5, Blood of the mother; Lane 6, Blood of the affected child. Scanned profiles of lanes 1, 4, and 6,
corresponding to the framed area, are presented in the right panel. For the sake of clarity, the plots of lanes 2 and 3 (which were similar to
that of lane 1) are not presented. Gel pictures were analyzed by use of NIH image software. Arrows indicate the position of the mutated
conformer in the different samples.
(Nussbaum et al. 1997), helped us characterize neo-
mutations. One neomutation arose in an affected child
in family LS07FR. No evidence for a somatic mosaicism
in her mother was found when other tissues (buccal-
swab, hair-root, and urinary cells) were tested (data not
shown). This result was in agreement with the absence
of ocular symptoms when a slit-lamp exam was con-
ducted on the mother. Two other neomutations arose in
the mothers of affected children: one on the chromosome
of grandpaternal origin (in family LS02FR) and one on
the chromosome of grandmaternal origin (in family
LS06ES). Interestingly, in family LS04FR, the OCRL1
mutation was not present in the apparently obligate-
carrier grandmother (individual I-2; fig. 1). Clinical mis-
diagnosis of the deceased affected boy (patient II-6) can
be ruled out, since this patient has been extensively clin-
ically documented as the first French patient with an
OCRL syndrome (Habib et al. 1962). As demonstrated
by analysis of the haplotypes, the grandmother has
transmitted three types of X chromosome to her off-
spring. The first chromosome X (haplotype 2-2-3-
OCRL1-1-1-3) is present in individuals with (patient II-
4) and without (individuals II-2 and II-8) the c1738g
mutation. The second chromosome X (haplotype 2-2-2-
OCRL1-3-1-4) is present in unaffected individuals II-5
and II-7. Clinical examination of the grandmother did
not reveal ocular symptoms. We therefore infer the pres-
ence of a germline mosaicism in the grandmother. To
distinguish pure germline mosaicism from somatic/germ-
line mosaicism, we tested three different tissues, besides
blood cells, for the c1738g mutation. As shown in figure
2, presence of the OCRL1 mutation was evident in uri-
nary cells. A conformer with the same electrophoretic
comportment (fig. 2, arrows) was present in DNA sam-
ples obtained either from the affected child (lane 6), the
carrier mother (lane 5), or the obligate carrier grand-
mother (lane 4). The weak signal obtained for the mu-
tated conformer in urinary cells of the grandmother in-
dicated that only a small fraction of these cells harbor
the mutation. In the same conditions, no mutated con-
former was detected in buccal swabs or hair roots of the
grandmother (fig. 2, lanes 2 and 3). These results clearly
indicate that, although the mosaicism within the grand-
mother is not generalized to all tissues, it is not strictly
restricted to the germinal cell line.
Discussion
Seven new mutations and one recurrent mutation were
identified in the OCRL1 gene in one carrier mother and
in seven affected patients. The screening strategy, based
on SSCA followed by the sequencing of the 23 coding
exons of the gene, appeared to be highly effective for
this gene, probably because of the short size of the exons
and because of their nucleotide content. Five of the eight
mutations identified led to the production of truncated
proteins. This is in good agreement with previously pub-
lished data (Lin et al. 1997) showing that 64% of all
mutations are nonsense or frameshift mutations leading
to a premature termination of OCRL1. One of the mu-
tations was a recurrent loss of a threonine at position
350 or 351 in one of the highly conserved domains of
the protein (fig. 3). This mutation has been shown pre-
viously to significantly decrease the 5-phosphatase ac-
tivity of OCRL1 (Lin et al. 1997).
One missense mutation was identified in exon 15. The
substitution changed the arginine residue at position 483
to a glycine. Two other reports have recently reported
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Figure 3 Blocks of highly conserved amino acid sequences shared by five human phosphoinositide and inositol polyphosphate 5-phos-
phatases. Numbers indicate the amino acid residue for each protein and are derived from their GenBank entries (OCRL1, U57627; INPP5B
[inositol polyphosphate 5-phosphatase type II], M74161; INPPL1 [inositol polyphosphate-like protein 1], L36818; SHIP [SH2-containing inositol
5-phosphatase], U57650; and synaptojanin, AF009040). Amino acids that are conserved in all five proteins are shaded. Amino acid changes
of OCRL1 that correspond to missense mutations or in-frame deletions associated with Lowe syndrome are indicated above the sequences.
Exon position is indicated below the sequences, and amino acids participating in the 5-phosphatase active site are dotted. Protein alignments
were performed by use of Megalign sofware (DNASTAR).
a change of this arginine residue into a glutamine in
unrelated families (Lin et al.1998; Kawano et al. 1997).
Owing to the use of a primal annotation of the OCRL1
cDNA (Attree et al. 1992), this mutation was referred
to as “R577Q” and was associated with a severe de-
crease in the amount of OCRL1 in the patient’s fibro-
blasts (Kawano et al. 1997). Therefore the R483 residue
appears critical in pathogenesis, since changes of this
amino acid represent 110% of all mutations described
so far in OCRL patients. Figure 3 presents sequence
comparisons between various human phosphoinositide
and inositol 5-phosphatases and shows that the highly
conserved R483 residue is located in a sequence motif
described as part of the active site of 5-phosphatases
(Jefferson and Majerus 1995). This motif was shown to
be involved directly in substrate binding in the 43-kD
inositol 5-phosphatase (Drayer et al. 1996). Further-
more, site-directed mutagenesis of the conserved argi-
nine in the type II inositol 5-phosphatase (R554) abol-
ishes its enzymatic activity (Jefferson and Majerus 1996).
On the basis of these data, the R483G mutation found
in the present study is likely to play a pathogenic role
in family LS04FR. Interestingly, 70% of the missense
mutations—which represent 30% of all mutations de-
scribed so far—are located in exon 15. This exon ap-
pears, therefore, to be a prime candidate when one is
searching for new mutations in families with Lowe syn-
drome. It should be noted that all missense mutations
described in exon 15 (except the V491D mutation) affect
well-conserved amino acids (fig. 3).
The frameshift mutation, 2799delC, located in the last
exon leads to a change of the last 26 C-terminal amino
acids. This mutation is a neomutation that arose in the
gametes of the grandfather (fig. 1). The C-terminal do-
main of OCRL1 shares no homology with that of other
inositol 5-phosphatases, and, to date, no specific func-
tion has been assigned to this region. However, it has
been postulated that domains outside the type II 5-phos-
phatase region are not essential for catalytic activity but
could influence regulation or localization of the protein
(Woscholski and Parker 1997). On the basis of protein-
sequence analysis using dedicated software, it was pre-
dicted that modification of the C-terminal domain, in-
duced by the 2799delC mutation, could lead to the loss
of potential phosphorylation sites and to the creation of
a putative myristoylation site. This could be of interest
if one considers that the C-terminal part of OCRL1 may
be involved in the regulation of enzyme activity. Since
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Figure 4 Schematic representation of exonic location of known mutations along the human OCRL1 gene. Exons are numbered 1–23,
with an alternatively spliced exon shown as 18a, in accordance with the report by Nussbaum et al. (1997). “Number of patients” refers to the
number of unrelated patients tested who had the same mutation. a  Leahey et al. 1993; b  Lin et al. 1997; c  Lin et al. 1998; d  Kawano
et al. 1998; e Kubota et al. 1998; f  present study.
the carrier mother (II-2, family LS02FR) is heterozygous
for the mutation and presents no clinical symptoms, one
may also conclude that the mutated OCRL1 exhibits no
deleterious effect. However, one cannot exclude the pos-
sibility that the modification of the C-terminus of
OCRL1 leads to a defect in the processing of the protein,
for instance in its localization or stability. Study of the
cellular localization of the mutant protein would be
therefore of interest to reveal a possible role played by
the C-terminal domain in the subcellular localization of
the protein and/or in the interaction with various or-
ganelles (Golgi complex, lysosomes). Unfortunately, fi-
broblasts from this family were not available at the time
of this study.
Search for mutations in families with Lowe syndrome,
based on SSCA prescreening and subsequent sequencing
of the genomic DNA, is a simple and convenient method
allowing, in most cases, both a direct diagnosis of car-
riers and prenatal diagnosis. When one considers the
distribution of mutations associated with Lowe syn-
drome reported so far in the literature, including the
seven new mutations described in this study, one can
clearly see that mutations are not uniformly distributed
throughout the OCRL1 gene (fig. 4). All mutations are
concentrated in only half of the 24 exons: exons 10–19
and 21–23. Interestingly, 52% of the OCRL1 mutations
cluster in five exons spanning the PtdIns(4,5)P2 5-phos-
phatase domain: exons 11–15. This percentage has fallen
from the 76% reported by Lin et al. (1998) but still
indicates that this region is a hot spot for mutations in
OCRL1 and should be considered a prime target when
one is looking for mutations.
Two new informative microsatellite markers closely
linked to the OCRL1 locus, DXS994 and DXS1047,
have been identified. These new markers map to a dis-
tance of 0 cM from the Lowe syndrome in the families
studied. Together with flanking DXS6854 and DXS6855
markers, these markers allow an efficient and infor-
mative haplotyping of the OCRL1 locus and can there-
fore be used for genetic counseling in the absence of a
characterized mutation. Haplotyping can also provide
additional information, such as the origin of the trans-
mitted chromosome in the case of a neomutation. Three
neomutations have been identified in this study, either
in affected children or in their mothers. The number of
neomutations found is in agreement with the rate of
spontaneous mutations expected for X-linked diseases.
On the basis of data generated by haplotyping and by
the identification of the OCRL1 mutation, a germline
mosaicism was suspected within the grandmother (pa-
tient I-2) of family LS04FR (fig. 1). As indicated in the
results section, the grandmother transmitted three types
of chromosome to her children, one of which bore the
R483G mutation. An alternative explanation to the pres-
ence of a germline mosaicism is the occurrence of two
independent neomutations in the affected boy (II-6) and
his carrier sister (II-4). Considering the rarity of Lowe
syndrome, this is unlikely. Furthermore, presence of a
mosaicism within the grandmother was confirmed by
analysis for the mutation in different tissues. As evi-
denced by results based on PCR analysis of urinary cells,
the mosaicism within the grandmother was a somatic/
germline mosaicism. Considering their embryogenic or-
igin and the fact that they can be easily obtained, urinary
cells may therefore be an interesting tissue to investigate
to distinguish between pure germline mosaicism and so-
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matic/germline mosaicism. This first description of a mo-
saicism present in the germline in a family with Lowe
syndrome has direct implications for genetic counseling.
Germline mosaicism associated with new mutations has
been well documented in X-linked diseases, especially in
Duchenne muscular dystrophy (DMD) after the first re-
ports by Bakker et al. (1987) and Darras et al. (1987).
In DMD the recurrence risk for a proved new mutation
was estimated to be 14%–18% when the haplotype at
risk is known (Bakker et al. 1987; van Essen et al. 1992)
and has been further refined by Passos-Bueno et al.
(1992) with regard to the site of the deletion: 30% for
a de novo proximal deletion and ∼4% for a distal one.
It is obvious that knowledge about the occurrence of
germline mosaicism is important for genetic counseling
and must be taken into account. In the case of OCRL
syndrome, evaluation of the recurrence risk will be dif-
ficult but can be bypassed if the mutation in a sporadic
case is identified and screened regardless of the mother’s
status.
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